Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
NephroGenex
company
About
NephroGenex is a drug-development company focusing on kidney disease and progression of diabetic kidney disease.
- 11 - 50
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $3.30M
- Industries
- Biotechnology,Diabetes,Health Care
- Founded date
- Jan 1, 2004
- Number Of Employee
- 11 - 50
- Operating Status
- Active
NephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorinâ„¢ (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$3.30M
NephroGenex has raised a total of
$3.30M
in funding over 2 rounds. Their latest funding was raised on
Jul 6, 2007 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 6, 2007 | Series A | $3.30M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
NephroGenex is funded by 1 investors.
Vanderbilt University Office of Investments
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Vanderbilt University Office of Investments
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
